Vect-Hours Closes $6.7M Funding Round

By StartUp City | Tuesday, September 29, 2020

Alexandre TOKAY, CEO

The company plans to use the capital to develop its programs and its first diagnostic and therapeutic agent's upcoming clinical trial.

FREMONT, CA: Vect-Horus, a Marseille, France-based biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, closed €6.7m ($7.89) in funding. Investors included historical shareholders and new entrants.

Led by Alexandre Tokay, Chairman, Vect-Horus designs and develops vectors that facilitate targeting and delivering therapeutic or imaging agents to organs, including the tumors and brain. The company combines these different agents to its vectors that specifically target various receptors, enabling these agents to cross natural barriers (first and foremost the blood-brain-barrier), which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models utilizing different vectorized molecules. Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder.

The company plans to use the capital to develop its programs and its first diagnostic and therapeutic agent's upcoming clinical trial. The proceeds of this new round of financing would enable the company to increase its R&D investments to optimize its VECTrans technology and, more specifically, to identify new vectors that will expand its portfolio. It will also allow for the development of new conjugates associating the company's vectors with therapeutic biomolecules: mRNAs, antibodies, and various antisense oligonucleotides, including siRNAs. Therefore, the vectorization potential of the VECTrans platform will be enhanced to achieve its targeted therapy objectives in multiple organs and indications.

Weekly Brief